New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer.

Autor: Hébert K; Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France., Bodin-Cufi P; Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France., Fersing C; Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France; Institut des Biomolécules Max Mousseron, University of Montpellier, Montpellier, France., Deshayes E; Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France; INSERM U1194, Institut de Recherche en Cancérologie de Montpellier, University of Montpellier, Montpellier, France. Electronic address: emmanuel.deshayes@icm.unicancer.fr.
Jazyk: angličtina
Zdroj: European urology focus [Eur Urol Focus] 2024 Aug 13. Date of Electronic Publication: 2024 Aug 13.
DOI: 10.1016/j.euf.2024.07.016
Abstrakt: Metastatic prostate cancer is a frequent and fatal disease. Targeted radionuclide therapy (TRT) has become a readily available therapeutic option since the approval of [ 177 Lu]Lu-PSMA-617. Various molecules are currently being studied for TRT in prostate cancer. We review various combinations of isotopes and vectors being used to target prostate cancer cells and optimize pharmacokinetics. Promising innovations include chemical modifications to improve biodistribution, identification of new targets, and the use of novel radioisotopes such as α emitters. PATIENT SUMMARY: Our mini review summarizes research on targeted radioactive drugs for treatment of metastatic prostate cancer. Several promising radioactive pharmaceuticals are being evaluated in clinical trials, but more studies are necessary before these can be used in routine clinical practice.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: